Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Terminated 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Breast 1

Conditions

Sarcoma 1Non-Squamous Non-Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × RG-1507 monoclonal antibody × Clear all
NCT00642941 2021-02-03

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

Hoffmann-La Roche

Phase 2 Terminated
317 enrolled 27 charts
Sarcoma

Sarcoma

NCT00760929 2021-01-05

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Hoffmann-La Roche

Phase 2 Terminated
171 enrolled 17 charts
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT00796107 2020-11-13

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Hoffmann-La Roche

Phase 2 Terminated
6 enrolled 5 charts
Breast

Breast Neoplasms

NCT00773383 2013-06-24

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

Hoffmann-La Roche

Phase 2 Terminated
35 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡